Relative Expression of IL-10 and TNF-α mRNA of Kidney and Spleen Tissues of Rat with and without Mammary Tumor after Exposure to Alternating Current Electric Field

Researchers have investigated a groundbreaking cancer treatment approach employing electric fields with varying direction and strength. These low-intensity electric fields, harmless to normal cells, disrupt the growth and division of cancer cells by influencing their internal structures. In a study involving rats with chemically induced breast cancer, the subjects were exposed to different electric field strengths. Assessments of two molecules linked to inflammation and immune response in the kidney and spleen indicated no adverse effects on these organs. Notably, there were signs that the electric fields might mitigate inflammation and enhance immune response in rats with breast cancer. The researchers concluded that electric fields are safe for the kidney and spleen in rats with breast cancer, underscoring the necessity for further studies to optimize their application and understand their mechanisms.

Key Findings

1. Impact on IL-10 mRNA Expression in Kidney Tissues: No significant changes in IL-10 mRNA expression were observed in the Non-Induced Non-Therapy (NINT) and Non-Induced Therapy (NIT) groups compared to the control group, indicating that ECCT does not induce substantial anti-inflammatory responses in non-tumor-bearing kidneys. A significant increase in IL-10 mRNA expression was seen in the Induced Non-Therapy (INT) group (p < 0.05), suggesting an inflammatory response to Tumorigenic agent-induced tumors. No significant changes were observed in the Induced Therapy (IT) group, although there were increasing tendencies, indicating that ECCT might have a mild anti-inflammatory effect in the presence of tumors.
2. Impact on IL-10 mRNA Expression in Spleen Tissues: No significant changes in IL-10 mRNA expression were observed across all groups, suggesting that ECCT does not significantly impact the spleen’s inflammatory response, even in tumor-bearing conditions.
3. Impact on TNF-α mRNA Expression in Kidney Tissues: No significant changes in TNF-α mRNA expression were observed across all groups, though there were decreasing tendencies. This indicates that ECCT does not induce a pro-inflammatory response in the kidneys and might slightly suppress pro-inflammatory signals.
4. Impact on TNF-α mRNA Expression in Spleen Tissues: No significant changes in TNF-α mRNA expression were observed across all groups, suggesting that ECCT does not enhance pro-inflammatory responses in the spleen.
5. No Adverse Effects on Normal Inflammatory Response: ECCT exposure did not significantly affect IL-10 and TNF-α mRNA expression in the kidneys of normal rats, indicating that ECCT does not induce harmful inflammatory responses in non-cancerous conditions and is safe for normal tissues.
6. Enhanced IL-10 Expression in Tumor-Bearing Rats: Significant upregulation of IL-10 mRNA in the INT group indicates an inflammatory response to Tumorigenic agent-induced tumors, possibly counteracting inflammation and oxidative stress.
7. TNF-α Expression Dynamics: The absence of significant changes in TNF-α expression across all groups suggests that ECCT does not exacerbate pro-inflammatory responses. The decreasing tendencies in TNF-α expression might indicate an inhibitory effect of IL-10, maintaining a balanced inflammatory response.
8. Non-Invasive and Safe Therapy: ECCT is a non-invasive treatment option with minimal adverse effects on healthy tissues, potentially enhancing the quality of life for cancer patients by reducing treatment-related side effects.
9. Potential for Combination Therapy: ECCT could be combined with other treatments to enhance therapeutic efficacy, leveraging its anti-inflammatory properties to mitigate the side effects of conventional therapies.
10. Safety and Efficacy of ECCT: The study indicates that ECCT does not significantly affect IL-10 and TNF-α expression in kidneys and spleens of rats, whether they have mammary tumors or not, suggesting that ECCT is a safe treatment modality without significant inflammatory or anti-inflammatory responses in vital organs.